Cite
HARVARD Citation
Da Silva, J. et al. (2020). FHITlow/pHER2high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy. Journal of pathology. 251 (2), pp. 187-199. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Da Silva, J. et al. (2020). FHITlow/pHER2high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy. Journal of pathology. 251 (2), pp. 187-199. [Online].